CONCLUSION: Due to its potential teratogenic effects, TPM has been classified as a pregnancy category D drug by major regulatory bodies, including the US FDA, EMA, TGA, and UK MHRA. Given the serious risks to fetal development, healthcare professionals must exercise careful consideration and diligent monitoring when prescribing TPM to women of childbearing age.
